The study, conducted by Case Western Reserve University School of Medicine in Cleveland, examined patient preferences for colorectal cancer screening modalities. Three-quarters of patients prefer stool DNA testing over colonoscopy, according to the study published in the journal Family Medicine and Community Health. Additionally, 84 percent of patients polled would repeat stool DNA testing if a provider recommended it.
Analysts Jeffrey Elliot and Catherine Ramsay of Robert W. Baird & Co. indicate the study’s results could have a positive impact Cologuard’s position with the USPSTF, according to the Milwaukee Business Journal.
More articles on gastroenterology:
ACG elects Dr. Kenneth DeVault president: 5 things to know
Commonwealth Laboratories, Quest Diagnostics sign agreement for IBSchek: 5 key notes
AGA calls for HHS to expand quality programs funding, support
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
